Trial
NCT04134468
MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Abramson Cancer Center at Penn Medicine
Collaborators
Halozyme Therapeutics
Condition
Pancreatic Ductal Adenocarcinoma
Intervention
Pegvorhyaluronidase alfa
Why stopped
Halozyme halted development of PEGPH20 following Phase 3 failure.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-01-31